ReviewHuman vaccines & immunotherapeutics2015
Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part II: Vaccines for Shigella, Salmonella, enterotoxigenic E. coli (ETEC) enterohemorragic E. coli (EHEC) and Campylobacter jejuni.
Review in Human vaccines & immunotherapeutics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 57 citations in OpenAlex.
- Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study.Clinical and vaccine immunology : CVI · 2016Trial
- Shigella flexneri and Shigella sonnei among children under five in Kenya's urban informal settlement.Gut pathogens · 2026Article
- Updated Estimates of the Global, Regional and National Burden, and Etiology of Diarrheal Diseases Transmissible via Food: A Systematic Review and Meta-Analytical Modelling Study for the World Health Organization.medRxiv : the preprint server for health sciences · 2026Article
- Optimization ofJournal of environmental engineering (New York, N.Y.) · 2025Article
- Multidrug-resistant ESBLHeliyon · 2025Article
- Subtractive proteomics and reverse-vaccinology approaches for novel drug targets and designing a chimeric vaccine againstFrontiers in immunology · 2025Article
- Validation of a Human Challenge Model Using an LT-Expressing EnterotoxigenicMicroorganisms · 2024Article
- Article
- Safety and Immunogenicity of a Chimeric Subunit Vaccine against Shiga Toxin-ProducingInternational journal of molecular sciences · 2023Article
- Immunologically effective biomaterials-enhanced vaccines against infection of pathogenic microorganisms.Biosafety and health · 2023Review
- A chimeric protein-based vaccine elicits a strong IgG antibody response and confers partial protection against Shiga toxin-producingFrontiers in immunology · 2023Article
- Protective Immunity Against Enterotoxigenic Escherichia coli by Oral Vaccination of Engineered Lactococcus lactis.Current microbiology · 2021Article
- Long-read-sequenced reference genomes of the seven major lineages of enterotoxigenic Escherichia coli (ETEC) circulating in modern time.Scientific reports · 2021Article
- Deciphering Additional Roles for the EF-Tu, l-Asparaginase II and OmpT Proteins of Shiga Toxin-ProducingMicroorganisms · 2020Article
- Inhibition of invasive salmonella by orally administered IgA and IgG monoclonal antibodies.PLoS neglected tropical diseases · 2020Article
- Article
- New Promising Targets for Synthetic Omptin-Based Peptide Vaccine against Gram-Negative Pathogens.Vaccines · 2019Article
- Coli Surface Antigen 26 Acts as an Adherence Determinant of EnterotoxigenicFrontiers in microbiology · 2018Article
- Ontology-based literature mining of E. coli vaccine-associated gene interaction networks.Journal of biomedical semantics · 2017Article
- Surface proteome mining for identification of potential vaccine candidates against Campylobacter jejuni: an in silico approach.Functional & integrative genomics · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In Part II we discuss the following bacterial pathogens: Shigella, Salmonella (non-typhoidal), diarrheogenic E. coli (enterotoxigenic and enterohemorragic) and Campylobacter jejuni. In contrast to the enteric viruses and Vibrio cholerae discussed in Part I of this series, for the bacterial pathogens described here there is only one licensed vaccine, developed primarily for Vibrio cholerae and which provides moderate protection against enterotoxigenic E. coli (ETEC) (Dukoral(®)), as well as a few additional candidates in advanced stages of development for ETEC and one candidate for Shigella spp. Numerous vaccine candidates in earlier stages of development are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.